Hepatitis C virus (HCV) is a major cause of severe liver disease, and one major contributing factor is thought to involve a dysfunction of virus-specific T-cells. T-cell receptor (TCR) gene therapy with HCV-specific TCRs would increase the number of effector T-cells to promote virus clearance. We therefore took advantage of HLA-A2 transgenic mice to generate multiple TCR candidates against HCV using DNA vaccination followed by generation of stable T-cell-BW (T-BW) tumour hybrid cells. Using this approach, large numbers of non-structural protein 3 (NS3)-specific functional T-BW hybrids can be generated efficiently. These predominantly target the genetically stable HCV genotype 1 NS3 1073-1081 CTL epitope, frequently associated with clearance of HCV in humans. These T-BW hybrid clones recognized the NS3 1073 peptide with a high avidity. The hybridoma effectively recognized virus variants and targeted cells with low HLA-A2 expression, which has not been reported previously. Importantly, high-avidity murine TCRs effectively redirected human non-HCV-specific T-lymphocytes to recognize human hepatoma cells with HCV RNA replication driven by a subgenomic HCV replicon. Taken together, TCR candidates with a range of functional avidities, which can be used to study immune recognition of HCV-positive targets, have been generated. This has implications for TCR-related immunotherapy against HCV.
INTRODUCTION
It is estimated that 180 million individuals are infected with hepatitis C virus (HCV) worldwide today, of which 130 million are chronic carriers at risk of developing liver cirrhosis and liver cancer. Being a small, enveloped RNA virus, HCV is one of the most persistent viruses in humans, and spontaneous resolution of HCV infection only occurs in a minority of the infected (Alter, 2006) . Considering the steady increase of reported incidence in Europe (Rantala & van de Laar, 2008) , a reduction of HCV prevalence is not anticipated in the near future.
Analyses of individuals who have resolved their HCV infection have indicated that a successful immunity requires effector T-cells. CD4
+ and CD8 + lymphocyte activation early in the infection is associated strongly with eradication of HCV infection (Cucchiarini et al., 2000; Diepolder et al., 1996; Lechner et al., 2000; Pape et al., 1999; Schulze zur Wiesch et al., 2005) , and an early development of polyfunctional T-cells further predicts a spontaneous resolution of HCV infection (Badr et al., 2008) . However, failure to sustain virus-specific CD8
+ lymphocytes is frequently observed in chronically infected patients (Lechner et al.,2005) , tolerance induction (Cabrera et al., 2004; Sugimoto et al., 2003) and impairment in proliferative capacity and effector function (Wedemeyer et al., 2002) , which are thought to be a consequence of continued antigen stimulation and/or a viral factor related to antigen-presenting cell (Bain et al., 2001; Goutagny et al., 2003; Nattermann et al., 2006; Ulsenheimer et al., 2005; Wertheimer et al., 2007) .
A successful immune response in people infected with HCV is characterized by strong and persistent CTL responses. One well-defined CTL epitope is the HCV non-structural protein 3 (NS3) [1073] [1074] [1075] [1076] [1077] [1078] [1079] [1080] [1081] peptide (NS3 1073 ), and responses against this epitope are often found in spontaneous resolution of HCV infection, which are well-maintained after spontaneous recovery of HCV (Wertheimer et al., 2003) . Several vaccines that target induction of NS3-specific T-cell immunity are currently being tested in clinical trials (Thompson & McHutchison, 2009) . Recently, a novel strategy for engineering new effector T-cells against NS3 1073 via gene transfer of a T-cell receptor (TCR) in vitro was described (Zhang et al., 2010) . Given the observation that the NS3 1073 epitope can be associated with cross-reactivity with an influenza A virus (IAV) neuraminidase (NA) epitope, and that cross-reactive CD8 + T-cells have been found in fulminant acute hepatitis patients (Urbani et al., 2005) , access to T-cells that differ in functional avidity would be desirable for comparison.
To date, only one NS3 1073 -specific human TCR (Zhang et al., 2010) has been identified and no murine alternatives are available. Murine TCRs present several advantages over human TCRs in gene modification of human T-cells, including an enhanced and more sustained level of surface expression and improved anti-tumour activity (Kieback & Uckert, 2010) . Moreover, a recent murine TCR gene-therapy trial that targeted tumour antigens demonstrated a therapeutic effect in cancer patients, although some immune responses to murine TCR variable regions were found in a subset of patients (Davis et al., 2010) . Given these facts, we therefore chose to explore the HLA-A2 transgenic (HHD) mouse model to establish more HCV TCR gene candidates. Here a large number of functional NS3-specific T-cell-BW (T-BW) hybrid clones were obtained by fusing the BW5147 cell line and activated splenocytes cells from HHD mice immunized with an electroporation-enhanced HCV NS3 DNA vaccine. The results indicate that the T-BW hybrid clones are highly specific to the NS3 1073 of HCV genotype 1a and 1b variants. Differences were found regarding their functional avidity and affinity to the NS3 1073 /HLA complex pentamer, as well as their ability to respond to human hepatoma cells harbouring HCV subgenomic RNA.
RESULTS
Generation of HLA-A2-restricted mouse T-BW hybrid clones specific to HCV NS3
We used CD8
+ T-cells from HHD (HLA-A2 transgenic) mice (Pascolo et al., 1997) immunized with the electroporation-delivered codon-optimized HCV DNA vaccine coNS3/ 4A-pVAX1, and performed cell fusion with BW TCR neg cells. Single-cell cloning was carried out under hypoxanthineaminopterin-thymidine (HAT) selection. T-BW hybridized clones that survived selection were screened for the surface expression of CD3 and positive clones were tested against human T2 cells (a lymphoblastic cell line) loaded with the HLA-A2-restricted NS3 1073 (CINGVCWTV) or NS3 1406 (KLVALGVNAV) peptide. Analysis of interleukin-2 (IL-2) and gamma interferon (IFN-c) release in the supernatant demonstrated that nine of them recognized the NS3 1073 -loaded T2 cells and none recognized that loaded with NS3 1406 (Fig. 1a) . The reactivity was confirmed by retesting on T2 cells as well as on HHD splenocytes (Fig. 1a-d) . TCR/CD3 surface expression for the respective clones was 51 % (I8H4), 81 % (I8A4), 79 % (I4G7), 85 % (I4F8), 95 % (I2B11), 95 % (I4E9), 84 % (I6B3), 52 % (I7B7) and 89 % (I4F9) at the time of the assays.
During the screening process, the hybrid clones were regularly subcloned and checked for CD3 expression to ensure that they maintained a stable CD3 expression and IL-2 activity ( Supplementary Fig. S1 , available in JGV Online). Although the clone I8A4 demonstrated repetitively low response against NS3 1073 , the percentage of live CD3-expressing cells and the cell-surface CD3 expression of this clone were similar to the others at the time of testing. None of the clones showed CD8 surface expression (data not shown), which is analogous to previous reported BWderived T-cell clones (Rock et al., 1990) ; thus, the cytokine release detected here is independent of the CD8 cofactor.
TCR gene usage of NS3 1073 -specific T-BW cell hybrid clones
Examination of the TCR usage of these T-BW hybrid clones was done in order to assess the TCR responsible for recognizing NS3 1073 . RNA was isolated from each of these clones and at least five TCR a and b gene products were sequenced. Sequence analysis showed that six of the nine clones were sister clones (Fig. 2a) ; AV9 and BV2 gene usage and an identical third complementarity-determining region (CDR3) sequence were found in I4F8, I2B11, I4E9, I6B3, I7B7 and I4F9. The AV9 gene was also used by I4G7, which has a unique CDR3 coding sequence using AJ27. The AV16 and AV2 genes were used by I8H4 and I8A4, respectively, and have their own CDR3 with different AJ genes. The TCR b genes were likewise determined for all clones. Three clones utilized VB13 with various subfamilies BV13-1 (I8H4), BV13-2 (I8A4), and BV13-3 and BV13-1 were found in I4G7 and they all used different BD and BJ genes. The I4F8 and its sister clones all used the BV2 gene and shared identical CDR3 nucleotide sequences.
Here, the CDR3a and CDR3b loops were between 10-13 and 11-14 aa residues, respectively. They exhibit a type II pattern bias (Turner et al., 2006) that is characterized by the preference of the motifs 'KLTFG' (CDR3a loops) and 'GG' (CDR3b loops). A commonly found motif in the BJ segments here was 'FGPGTR', which is reported only in three out of 13 murine and four out of 14 human TRBJ genes (IMGT Repertoire IG and TR database; http://www. imgt.org/IMGTrepertoire/). Interestingly, the same three motifs also exist in a recently reported human TCR that is specific to the NS3 1073 peptide (Zhang et al., 2010) . This result suggests that highly conserved CDR3 motifs are shared by the murine and human TCRs that are specific to the NS3 1073 peptide.
Affinity to NS3 1073 /HLA-A2 pentamer
Since the T-BW hybrid clones lack the CD8 coreceptor, which might be required for the stabilization of the TCRpeptide/HLA complex (Roszkowski et al., 2003) , we next asked whether any of these clones could bind the NS3 1073 / HLA-A2 pentamer. Following incubation with an Rphycoerythrin (R-PE)-labelled NS3 1073 /HLA-A2 pentamer, the fluorescence intensity of the staining was quantified by flow cytometry. Compared with the negative-control pentamer HBVcore 18-27 -HLA-A2, it was found that I8H4, one of the high-avidity clones, had an increased fluorescence in NS3 1073 /HLA-A2 pentamer staining (Fig. 2b) .
Comparison of the functional avidity
We next asked whether the functional avidity in these Tcell hybrid clones might differ. The clones were regularly subcloned and checked by FACS and were tested when the TCR/CD3 expression was at least 50 % at the time of the experiment. They were tested with T2 target cells pulsed with diluted amounts of NS3 1073 peptide and the results showed that, while I8A4 required at least 400 ng peptide ml 21 to obtain a half-maximum response of IL-2 release, about 10 ng peptide ml 21 was sufficient for stimulating I8H4, I4G7 and I4F8 for a half-maximum response of IL-2 release (Fig. 3) . The TCR/CD3 surface expression was 51 % (I8H4), 82 % (I8A4), 88 % (I4G7) and 93 % (I4F8) at the time of this experiment. The experiment was performed three times with similar results. Based on these data, I8A4 is ranked as a low-avidity T-cell clone, while I8H4, I4G7 and I4F8 resemble moderate/high-avidity T-cells described previously (McKee et al., 2005) .
Cross-genotype reactivity
We next asked whether these clones cross-reacted with other viral peptides, in particular the naturally occurring genotypes of HCV NS3 1073 and the IAV NA, Flu-NA 231 , to which cross-reactivity to HCV NS3 1073 of genotype 1b strain has been described (Wedemeyer et al., 2001) . Shown in Fig. 4 , we found that these T-cell clones were activated only when cultured with the genotype 1a and 1b peptide of the HCV NS3 1073 . None of the other HCV genotype peptide variants tested was sufficiently stimulatory to induce substantial IL-2 production, although all variants displayed significant binding affinity to the HLA-A2 molecule (Fytili et al., 2008) . No IL-2 production was found against the Flu-NA peptide (Fig. 4) or other viral peptides, including the HCV non-structural protein 5 (NS5) peptide NS5 2221 and NS5 1992 SPDADLIEANL and VLTDFKTWL, and human cytomegalovirus (HCMV) pp65 495 NLVPMVATV (data not shown). The TCR/CD3 surface expression was 97 % (I8H4), 70 % (I8A4), 99 % (I4G7) and 95 % (I4F8) at the time of this experiment. The T-cell receptors against HLA-A2-restricted HCV NS3 antigen results suggest that these T-cell clones are highly specific for genotype 1 of HCV NS3.
Relevance of each amino acid position of NS3 1073 peptide for hybridoma reactivity Since amino acid positions 2, 7, 9 and positions 3, 4, 5 of NS3 1703 are key positions in HLA binding and interaction with human TCR (Söderholm et al., 2006) , respectively, we next tested whether they have relevance for the four murine T-BW hybrid clones, 18H4, 18A4, 14G7 and 14F8. Alaninesubstituted peptide analogues of NS3 1073 loaded ono T2 cells in descending concentrations were tested against these T-cell clones. As shown in Fig. 5 , alanine substitutions at position 3, 4, 5 and 7 completely abolished the IL-2 release in all four T-cell clones, which is in line with that observed for human T-cells. Complete or partial IL-2 release in response to alanine substitutions at position 1, 2, 6, 8 and 9 was, however, obtained in high-avidity clones, and was also observed at reduced peptide concentrations. This was unfortunately not observed for I8A4 (low avidity), which responded only to alanine substitution at position 1 and none of the other substitutions. The TCR/CD3 surface expression was 51 % (I8H4), 82 % (I8A4), 88 % (I4G7) and 93 % (I4F8) at the time of this experiment.
Recognition of target cells with low HLA-A2 expression
T2 cells are a lymphoblastic cell line commonly used as antigen-presenting cells for loading exogenous peptide and, due to the constitutive HLA-A.2 expression and TAP (transporter associated with antigen processing) deficiency, the density of these target molecules is often saturated. We next asked whether our T-cell hybrid clones recognize target cells that have low HLA-A2 expression. The hepatoblastoma Huh-6 and C1R-A2 cell lines were chosen for this experiment. Cell-surface expression of HLA-A2 assessed by staining with an anti-HLA-A2 mAb (Fig. 6a) after NS3 1073 peptide stabilization showed that both cell lines have lower HLA-A2 expression than T2 cells. Huh-6 cells showed the lowest HLA-A2 expression, as only a fraction of the cells were positive for staining compared with the negative-control C1R-null cell line (Fig. 6b) . We then assessed IL-2 production in the T-cell clones cocultured with these target cells. Shown in Fig. 6(c) , NS3 1073 peptide-loaded C1R-A2 cells could stimulate significant IL-2 production in all four T-cell lines, at a similar magnitude to that observed for the T2 target cells. Significant IL-2 release against the peptide-loaded Huh-6 cells was, however, T-cell receptors against HLA-A2-restricted HCV NS3 antigen only detected in the high-avidity clones, especially the I8H4 clone (Fig. 6d) . TCR/CD3 surface expression was 90 % (I8H4), 80 % (I8A4), 89 % (I4G7) and 90 % (I4F8) at the time of this experiment.
Reactivity against HCV RNA replicon hepatoma cells
We next analysed the ability of the T-cell hybrids to recognize the Huh-7/Lunet HCV replicon cells that harbour the subgenomic HCV replicon. Huh-7/Lunet hepatoma replicon cells maintain constant levels of HCV replication over several years and represent an excellent model of persistent HCV infection (Bartenschlager & Sparacio, 2007) . As Huh-7 cells lack HLA-A2 expression, they are stably transduced with lentiviral vectors expressing HLA-A2 and a selectable marker encoding the blasticidinresistance gene, and transfected with the HCV genotype 1b Con1-ET subgenomic replicon and a selection marker conferring the neomycin-resistance gene by using an approach described previously (Ahlén et al., 2007) . As shown in Fig. 7(b) , antigen-specific IL-2 production by the T-cell clones was detected after co-culture at different ratios with peptide (NS3 1073 genotype 1a)-loaded HCV replicon cells harbouring both the Con1-ET replicon and HLA-A2 (R-neo/A2) or control cells expressing only the HLA-A2 (A2). In these cultures both IL-2 and IFN-c were detected, particularly from the high-avidity I8H4, I4F8 and I4G7 T-cell clones, and this indicates that the lentiviraltransferred HLA expression is functional. The TCR/CD3 surface expression was 90 % (I8H4), 80 % (I8A4), 89 % (I4G7) and 90 % (I4F8) at the time of the experiment. In the same experiment, we investigated whether these T-cell clones recognized the replicon cells directly without addition of exogenous peptide. Shown in Fig. 7(a) , IL-2 production was detected in the co-culture of the I8H4 and HLA-A2-positive HCV replicon cells (R-neo/A2), and this IL-2 production was dependent on the ratio of the added cells. No IFN-c was detected (data not shown). Stimulation with HCV replicon cells without HLA-A2 expression or cells with HLA-A2 expression only did not stimulated any IL-2 release from the I8H4. This result concurs with previous results that I8H4 is the only clone with affinity to the NS3 1073 /HLA-A2 pentamer (Fig. 2) and has an increased response to genotype 1b sequence (Fig. 4) and the Huh-6 target cells (Fig. 6) .
Transfer of TCR genes into naïve non-HCV specific human T-cells
Although BW hybridomas are a good model to assess TCR functions, they have a limited clinical application in humans. To know whether murine TCRs identified here are functional to redirect non-HCV-specific human 
T-lymphocytes against HCV
+ cells, peripheral blood lymphocytes (PBLs) from healthy human donors were thus transduced with retroviral vectors packaged with genes encoding I8H4 TCR and the I4F8 TCR, which reacted strongly against the NS3 1073 peptide in previous experiments. Surface expression of the respective TCRs following retroviral transduction was detected following transduction in 10-20 % CD3
+ T-cells and not noticeably in mock, untransduced PBL controls (,0.15 %) stained with the mouse Vb antibodies. Transduced T-cells, here defined as mouseVb + humanCD8 + -expressing cells, were found to produce significant amounts of IFN-c when stimulated with NS3 1073 1a or 1b peptide-loaded T2 cells (Fig. 8a) . Tumour necrosis factor alpha (TNF-a) was found frequently in this IFN-c + population and a 'triple'-positive population (IL-2
was clearly demonstrated (Fig. 8b ). The CTL function was studied on luciferase-producing bioluminescent Huh-7/Lunet HCV replicon cells (HLA-A2 + Luc-ubi-neo Con1 + ) that had been co-incubated with transduced T-cells using a charge-coupled device (CCD) camera. Images were taken at 20 h after co-incubation and analysed by Living Image software (version 4.2; Caliper Life Sciences). The analysis showed an efficient elimination of bioluminescent HCV replicon cells that have been coincubated with I4F8 and I8H4 TCR-transduced T-cells (Fig. 8c, d) , and a significant increase of hepatocellular aspartate transaminase was also detected in these co-culture supernatants when compared with those co-incubated with mock-transduced T-cells (Fig. 8e) . In conclusion, our data indicate that murine TCRs identified by the current approach can provide antigen specificity to naïve non-HCVspecific T-cells to generate new effector T-cells that are polyfunctional and can eliminate HCV RNA-replicating hepatoma cells.
DISCUSSION
In this study, we describe identification of new HCVspecific T-cell clones in the HLA-A2 transgenic mouse T-cell receptors against HLA-A2-restricted HCV NS3 antigen model generated by DNA vaccination by electroporation and stable immortalization of these T-cell clones via somatic-cell hybridization with the BW5147 cell line. These T-cell clones recognize the NS3 1073 epitope, which is one of the most important CTL epitopes in hepatitis C often associated with spontaneous resolution of HCV infection (Wertheimer et al., 2003) . As shown here, they are highly specific to NS3 1073 and cross-recognition is restricted within genotype 1a and 1b virus variants and not to other related viral sequences tested. This is interesting because genotypes 1a and 1b viruses are found in up to 70 % of infected patients in the USA and Europe. Moreover, these clones differ from each other with regard to their functional avidity and affinity. This resembles the discrepancy in T-cell avidity observed in humans between donors who have recovered from HCV infection and chronically infected patients (Neveu et al., 2008) . In this regard, the high-avidity clones I8H4, I4G7 and I4F8 generated in this study have similar EM 50 (effective molarity) values (approx. 10 ng ml
21
) to those found in CD8 + T-cells in individuals who have recovered from HCV infection, while clone I8A4, which has a 10-100-fold-higher EM 50 value (400 ng ml 21 ), resembles the T-cells found in chronically infected patients (Neveu et al., 2008) . Furthermore, there has been an elegant study by Kasprowicz et al. (2008) in which it was demonstrated that NS3 1073 -specific T-cells that are CD8-independent might represent cells of higher functions, i.e. require substantially less viral peptide as well as fewer cells to achieve the effector function. This might be of relevance for the mouse TCRs reported here, as they were raised in the absence of human CD8 and are capable of recognizing the target cells in a CD8-independent manner.
To our knowledge, this is the first study that has examined the TCR repertoire that is induced by an HCV vaccine. The TCR repertoire induced by natural infection of HCV has so far described the b chain (Miles et al., 2011) , but it is interesting to find that our murine TCRs not only share similar CDR3 lengths to those found there, but also the same sequence motifs found in a human NS3 1073 TCR (Zhang et al., 2010) . Given the conserved nature of these motifs, it is likely that they play a key role in the interface between TCR and antigen contacts, tickling the T-cell to respond.
Moreover, our report is the first to demonstrate that HCVspecific T-cell hybridomas of different functional avidities towards a human HCV CTL target can be generated rapidly by DNA vaccination of HHD mice. Studies of HCV antigen presentation often require substantial amounts of HCVspecific lymphocytes/primary human T-cells (Accapezzato et al., 2005; Barth et al., 2005 Barth et al., , 2008 Lapenta et al., 2006) but, because of the short lifespan and the requirement of repetitive antigen stimulation with primary T-cell lines, an alternative approach to obtaining large amounts of HCVspecific T-cells would be of interest. The T-cell hybrid clones presented here could be useful reporter T-cells with mouse cytokines as reporter protein; unlike primary T-cell clones, they do not require maintenance through antigen stimulation or cytokine growth factors, but grow vigorously in simple cell-culture medium without special supplements. Their activity does not fluctuate in a cyclical manner, as occurs with some antigen-stimulated T-cell clones. Freezing and recovery are easy and, moreover, good viability and activity are usually observed. Some limitations need to be considered here. One is that avidity is determined in peptide-titration assays and not by the offrate of pentamers after binding to the TCR. The second is that BW-derived hybrids lack CTL function because CD8 expression is suppressed (Rock et al., 1990) .
Despite the fact that only one hybridoma (I8H4) here recognized endogenously processed antigen from human hepatoma cells that replicate HCV RNA, we note that functional properties were further improved when I8H4 and I4F8, the latter also a high-avidity TCR, were genetically transferred and expressed on naïve non-HCV-specific human peripheral T-lymphocytes. Both murine TCRs were highly functional in human CD8 T-cells to give rise to antigen-specific polyfunctional human CD8 + T-cells capable of demonstrating at least four effector functions, including eliminating HCV genotype 1b replicon cells and causing aspartate aminotransferase (AST) enzyme release. This is encouraging, as polyfunctional effector T-cells capable of IL-2 production are associated with effective control of HCV (Ciuffreda et al., 2008) and represent an important feature in protective T-cell memory induced by highly efficacious human vaccines (Ahmed & Akondy, 2011) . Because HCV genotype 1 is in general associated with drug resistance, the notion that our TCRs can crossrecognize genotype 1a and genotype 1b viral peptides makes them interesting as immunotherapy candidates.
It is true that we have failed to induce NS3 1406 T-cells in this study, because in HLA transgenic mice they are better induced by peptide vaccination (Brinster et al., 2001) . However, with the current approach we have now generated new TCRs that target NS5 CTL epitopes that are associated with control of acute self-limited hepatitis C (A. Pasetto and others, unpublished data). With the bioluminescent HCV replicon cells as an indicator for CTL efficiency, it would be interesting to compare the antiviral potentials in TCRmodified effector T-cells with various peptide specificities.
In summary, the current study has demonstrated an efficient way to generate TCR candidates that range in different functional avidities, with specificity against an important HCV CTL target. It has implications on the development of HCV immunotherapy and the understanding of T-cell recognition of HCV-infected cells. Plasmids and synthetic peptides. The plasmid coNS3/4A-pVAX1, containing the full-length codon-optimized NS3/4A gene of HCV genotype 1a, has been described previously (Frelin et al., 2003 (Frelin et al., , 2004 Endogenous peptides bound to HLA-A2 molecules on C1R-A2 cells were removed by mild acid treatment (pH 3.3) and replaced by HCV NS3-specific HLA-A2 peptides (Jäger et al., 1999) . All media and supplements were purchased from Invitrogen.
METHODS
Generation of HCV NS3-specific T-BW hybridoma clones.
Splenocytes and lymph node cells were isolated from coNS3/4A-DNA immunized HHD-C57BL/6 mice as described previously (Ahlén et al., 2007) . Following 5 days stimulation with HCV NS3 peptides, CD8
+ T-cells were purified using CD8 MACS MicroBeads (Miltenyi Biotec) and fused to BW TCR neg cells. Briefly, the CD8 + cells were mixed with BW TCR neg cells in a 1 : 5 ratio and PEG1450 (Sigma) was added; thereafter, the cells were resuspended in minimal essential medium (MEM) and incubated for 5 min at 37 uC, and cultured for 48 h before selection in HAT (Sigma Aldrich) and HT (HAT without aminopterin; Gibco, Invitrogen) media. Hybridized cell clones were maintained in complete BW medium. Positive clones were retested and regularly subcloned and checked for CD3 expression.
HCV replicon cells. Hepatoma Huh-7-Lunet cells designated LunetHlaA2-neoET, Lunet-blr/neo ET or Lunet-HlaA2 (neo) or Lunet-HLA-A2-Luc-ubi-neo Con1 were generated by rotocol similar to that described previously (Ahlén et al., 2007) . The Lunet-HlaA2-neoET has ectopic HLA-A2 expression and a selectable HCV subgenomic RNA replicon of genotype 1b, harbouring replication-enhancing mutations in NS3 and NS4B (Con1-ET). This is the same for Lunet-HLA-A2-Luc-ubi-neo Con1, but it also co-expresses the firefly luciferase gene. The control replicon cell line Lunet-blr/neo ET was transduced with an empty viral vector without the HLA-A2 gene. These cells were maintained in complete DMEM with addition of blasticidin S hydrochloride (3 mg ml
21
) and G418 (1 mg ml
). Lunet-HlaA2, the other control cell line (expressing HLA-A2 under blasticidin selection but without the HCV replicon), was maintained in the same DMEM as above but with 3 mg blasticidin S hydrochloride ml 21 and no G418. For the co-culture experiments, the Lunet cells were washed and reseeded 1 day before in antibiotic-free medium. All medium and supplements were purchased from Invitrogen.
Antibodies and flow cytometry. Antibodies against mouse CD3, CD8 and human HLA-A2 (BD Biosciences), and R-PE-labelled HLA-A*0201 Pro5 pentamers refolded with HCV NS3 1073 or HBV core [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] (ProImmune) were used. For intracellular multicolour FACS staining, TCR-transduced PBMCs were incubated overnight with indicated stimuli. GolgiPlug (BD Biosciences) was added during the final 12 h. PMA at 50 ng ml 21 and ionomycin at 500 ng ml 21 (Sigma) were used as a positive control. Cells were then washed and stained with: Pacific Blue-anti-human CD3 (Biolegend), allophycocyanin-Cy7-anti-human CD8a (Biolegend), FITC-labelled anti-mouse Vb 8.3 (BD Biosciences), anti-mouse Vb8.1-8.2 (BD Biosciences), anti-mouse Vb6 (BD Biosciences), anti-mouse Vb4 (BD Biosciences), allophycocyanin-anti-human IL-2 (Biolegend), PE-anti-human IFN-c (Biolegend) and PE-Cy7-anti-human TNF (BD Biosciences). A BD Cytofix/Cytoperm fixation/permeabilization kit was used. Cells were analysed using a BD LSRFortessa flow cytometer and FlowJo 9.2 (Tree Star) software.
Measurement of cytokine release. Target cells (2610 5 ) were cultured for 24 or 48 h with equal numbers or the indicated number of each BW-T cell hybrid clone in duplicates with or without different viral peptides. Concentrations of mouse IL-2 and IFN-c in the supernatant were measured using mouse IL-2 or IFN-c ELISA (Mabtech) and calculated against standard curves generated with a cytokine standard.
TCR gene typing and sequencing, and retroviral TCR constructs. Total RNA was reverse-transcribed to cDNA using SuperScipt III RT enzyme (Invitrogen). TCR variable alpha (VA) and variable beta (VB) chain typing was done by PCR with Platinum Taq polymerase (Invitrogen) and primer sets covering the entire murine TCR VA and VB repertoire. PCR products were cloned (pCR-4 TOPO system, Invitrogen) and the plasmids were sequenced by Eurofins MWG (Ebersberg). Sequences were analysed and classified according to the nomenclature given in the Immunogenetics database (European Bioinformatics Institute, Cambridge, UK). Full-length TCR genes were amplified and, after sequence confirmation, synthetic genes linked with the autoprotease 2A sequence were made (GeneArt, LifeTechnology) and assembled into pMP-71-G-Pre retroviral plasmid (kindly provided by Wolfgang Uckert, Max-Delbrück-Center for Molecular Medicine). Phoenix amphotropic packaging line (Nolan's lab, Standford University) was used to package the expression plasmids for expression in primary human T-cells. Calcium phosphate transfection was done with 20 mg of each vector (pMP71-NS3-H4, pMP71-NS3-F8, pMP71-NS5-19, pMP71-NS5-69 and pMP71-EGFP) and 12.5 ml of 50 mM chloroquine.
Retrovirus transduction. Human PBMCs were stimulated with 600 or 300 U IL-2 ml 21 (R&D System or Prepotech) and 50 ng anti-CD3 ml 21 (OKT-3 eBioscience). Lymphocytes were harvested and transduced by spinoculation on retronectin-coated wells with polybrene (Millipore). Spinoculation was repeated the next day and TCR surface expression was analysed by FACS 72 h after the first spinoculation.
Bioluminescence cell imaging and transaminase measurement. Either 50 000 or 100 000 Lunet-HlaA2-Luc-ubi-neo Con1 cells were co-cultured with transduced or mock-transduced T-cells in a ratio of 2 : 1. Following 20 h co-incubation the medium was replaced with luciferin solution prior to imaging with a chargecoupled device camera. Signals from bioluminescent Lunet-HlaA2-Luc-ubi-neo Con1 cells were analysed with the Living Image Software version 4.2 and IVIS Spectrum instrument (Caliper Life Sciences). The AST level in supernatants was quantified by a validated AST assay at the Clinical Chemistry Laboratory at the Karolinska University Hospital.
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